Is fish intake linked to juvenile idiopathic arthritis?

  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 46 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 39%
  • Publisher: 51%

Medicine Research News News

Medicine Research,Health Research News,Health Research

Juvenile idiopathic arthritis (JIA) results from a complex interplay of genetic and environmental factors. Past efforts to identify JIA's environmental risk factors have been restricted due to limited high-quality data and small sample sizes, mirroring the rarity of the disease.

Is fish intake linked to juvenile idiopathic arthritis? retrieved 14 June 2024 from https://medicalxpress.com/news/2024-06-fish-intake-linked-juvenile-idiopathic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Mar 16, 2020Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 101. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Trametinib shows promise for children with relapsed or refractory juvenile myelomonocytic leukemiaThe MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a Phase II clinical trial, with seven of 10 patients alive after a median of two years, according to results published in Cancer Discovery.
Source: medical_xpress - 🏆 101. / 51 Read more »